Lipid-based oral multiparticulate formulations-advantages, technological advances and industrial applications

Expert Opinion on Drug Delivery

Volumn 8, Issue 2, 2011, Pages 207-224

  Shukla, Dali ^a   Chakraborty, Subhashis ^a   Singh, Sanjay ^a   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

drug delivery; formulation technology; lipid; liposomes; pastillation; solid lipid nanoparticles; solid lipid pellets; solid self emulsifying drug delivery systems

Indexed keywords

ACAMPROSATE; ACEBUTOLOL; ACICLOVIR; ALFUZOSIN; ALISKIREN; ALVIMOPAN; AMFEBUTAMONE; AMIODARONE; AMPHOTERICIN B LIPID COMPLEX; ATENOLOL; ATOMOXETINE; ATORVASTATIN; ATOVAQUONE; AZITHROMYCIN; BROMOCRIPTINE MESILATE; BUSPIRONE; CANDESARTAN HEXETIL; CARVEDILOL; CEFDITOREN PIVOXIL; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSPORIN A; DARIFENACIN; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; LIPID; LIPOSOME; NANOPARTICLE; UNINDEXED DRUG;

AEROSOL; CHEMICAL MODIFICATION; COOLING; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; EMULSION; EVAPORATION; EXTRUSION; FREEZE PELLETIZATION; HOMOGENIZATION; HOT MELT EXTRUSION; HUMAN; MELT GRANULATION; NONHUMAN; PASTILLATION; PROCESS TECHNOLOGY; REVIEW; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SPHERONIZATION; SPRAY CONGEALING; SPRAY DRYING; SUSPENSION; TABLET FORMULATION; ULTRASOUND; WET GRANULATION;

DRUG CARRIERS; DRUG COMPOUNDING; LIPIDS; MICROSPHERES; NANOSPHERES; NANOTECHNOLOGY; PHYSICOCHEMICAL PHENOMENA;

EID: 79251476579     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.547469     Document Type: Review

References (128)

1. Stegemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 2007;31:249-61
2. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009;73:1-15
3. Drewe J, Meier R, Vonderscher J, et al. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 1992;34:60-4
4. Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter-and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444-6
5. Odeberg JM, Kaufmann P, Kroon KG, et al. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. Eur J Pharm Sci 2003;20:375-8
6. Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001;50:61-80
7. Sood A, Ashokraj Y, Panchagnula R Multiunit matrix based particulate systems (MUMPS) for controlled delivery of nifedipine. Formulation development using extrusion-spheronization and in vitro evaluation. Pharm Tech 2004;28:62-71
8. Bechgaard H, Nielsen G. Controlled release multiple units and single unit doses. Drug Dev Ind Pharm 1978;4:53-7
9. Celik M. Multiparticulate oral drug delivery. Marcel Dekker, New York; 1994. p. 181
10. Gu L, Liew CV, Heng PWS. Wet spheronization by rotary processing-a multistage single-pot process for producing spheroids. Drug Dev Ind Pharm 2004;30:111-19
11. Reynolds AD. A new technique for the production of spherical particles. Manuf Chem Aeros News 1970;41:40-3
12. Guidance for Industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidaances/ucm070124. pdf [Last accessed 10 September 2010]
13. Bechgaard H, Nielsen GH. Controlled-release multiple-units and single-unit doses-A literature review. Drug Dev Ind Pharm 1978;4:53-67
14. Ito Y, Arai H, Uchino K, et al. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm 2005;289:69-77
15. Tuleua C, Andrieuxb C, Boyc P, Chaumeila JC Gastrointestinal transit of pellets in rats: effect of size and density. Int J Pharm 1999;180:123-13
16. Vervaet C, Baert L, Remon JP. Extrusion-spheronization: a literature review. Int J Pharm 1995;116:131-46
17. Aulton ME, Dyer AM, Khan KA. The strength and compaction of millispheres. Drug Dev Ind Pharm 1994;20:3069-104
18. Obaidet AA, Obaidet RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm 2001;52:231-5
19. Schwab M, Sax G, Schulze S, Winter G. Studies on the lipase induced degradation of lipid based drug delivery systems. J Control Release 2009;140:27-33
20. Chonna A, Cullis PR Recent advances in liposome technologies and their applications for systemic gene delivery. Adv Drug Deliv Rev 1998;30:73-83
21. James MB, Elliott LG. Pharmaceutical composition comprising cefuroxime axetil. US4865851; 1989
22. Rxlist. Available from: www.rxlist.com [Last accessed 10 September 2010]
23. Gupta MK, Goldman D, Bogner RH, et al. Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent. Pharm Dev Technol 2001;6:563-72
24. Duzgunes N. Methods in enzymology, liposomes. Volume 391. Elsevier Academic Press, CA, USA; 2005. p. 71-96
25. Kshirasagar NA, Bodhe PV, Kotwani RN. Targeted drug delivery in visceral leishmaniasis. J Par Dis 1997;21:21-4
26. Gokhale PC, Kshirsagar NA, Khan MU, et al. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. Trans Roy Soc Trop Med Hyg 1994;88:228
27. Karande SC, John Boby KF, Kshirsagar NA. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-amp-LRC) in child. Trop Doc 1995;25:80-1
28. Banerjee G, Nandi G, Mahato SB, et al. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 1996;38:145-50
29. Kotwani RN, Gokhale PC, Kshirsagar NA, Pandya SK. Optimizing dosage regimens of liposomal amphotericin B using Aspergillus murine model. Indian J Pharmacol 1996;28:88-92
30. Mukhopadhyay A, Mukhopadhyay B, Basu K. Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. FEBS Lett 1995;276:95-8
31. Sharma D, Chelvi TP, Kaur J, Ralhan R Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melan Res 1998;8:240-4
32. Sharma D, Chelvi TP, Kaur J, et al. Novel taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res 1996;8:281-6
33. Jain NK, Rana AC, Jain SK. Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism. Drug Dev Ind Pharm 1998;24:671-5
34. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997;1334:161-72
35. Okada J, Cohen S, Langer R In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm Res 1995;12:576-82
36. Chen H, Torchilin V, Langer R Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 1996;13:1378-83
37. Lasic DD. Novel applications of liposomes. Trends Biotechnol 1998;16:307-21
38. Uppadhyay AK, Dixit VK. Bioadhesive liposomes bearing levonorgestrel as controlled drug delivery system. Pharmazie 1998;53:421-2
39. Cao J, Sun J, Wang X, et al. N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm 2009;35:1339-47
40. Smith AM, Jaime-Fonseca MR, Grover LM, et al. Alginate-loaded liposomes can protect encapsulated alkaline phosphatase functionality when exposed to gastric pH. J Agric Food Chem 2010;58:4719-24
41. Werle M, Makhlof A, Takeuchi H. Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem Pharm Bull 2010;58:432-4
42. Anderson KE, Eliot LA, Stevenson BR, Rogers JA. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm Res 2001;18:316-22
43. Al-Meshal MA, Khidr SH, Bayomi MA, Al-Angary AA. Oral administration of liposomes containing cyclosporine: a pharmacokinetic study. Int J Pharm 1998;168:163-8
44. Degim Z, Unal N, Essiz D, Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci 2004;75:2819-27
45. Crowe JH, Spargo BJ, Crowe LM. Preservation of dry liposomes does not require retention of residual water. Proc Natl Acad Sci USA 1987;84:1537-40
46. Schreier H, Mobley WC, Concessio N, et al. Formulation and In vitro performance of liposome powder aerosol. STP Pharm Sci 1994;4:38-44
47. Mayhew E, Nikolopoulos GT, King JJ, Siciliano AA. A practical method for the large scale manufacture of liposomes. Pharm Manufact 1985;2:18-22
48. Payne NI, Browning I, Hynes CA. Characterization of proliposomes. J Pharm Sci 1986;75:330-3
49. Maierhofer G. Liposomes: preparation and application. Am Clin Prod Rev 1985;4:33-44
50. Mozafari MR, Reed CJ, Rostron C. Development of non-toxic liposomal formulations for gene and drug delivery to the lung. Technol Health Care 2002;10:342-4
51. Mozafari MR, Reed CJ, Rostron C, et al. Construction of stable anionic liposome-plasmid particles using the heating method: a preliminary investigation. Cell Mol Biol Lett 2002;7:923-7
52. Mozafari MR, Reed CJ, Rostron C, Martin DS. Transfection of human airway epithelial cells using a lipid-based vector prepared by the heating method. J Aerosol Med 2004;17:100
53. Muller RH, Ruhl D, Runge S, et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997;14:458-62
54. Sharma P, Ganta S, Denny WA, Garg S. Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: chlorambucil. Int J Pharm 2009;367:187-94
55. Liu W, Hu M, Liu W, et al. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm 2008;364:135-41
56. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008;70:633-40
57. Mehnert W, Mader K. Solid lipid nanoparticles\production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96
58. Westesen K, Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int J Pharm 1995;115:129-31
59. Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm 2008;359:104-10
60. Kamiya S, Yamada M, Kurita T, et al. Preparation and stabilization of nifedipine lipid nanoparticles. Int J Pharm 2008;354:242-7
61. Pozo-Rodriguez AD, Pujals S, Delgado D, et al. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release 2009;133:52-9
62. Li HL, Zhao XB, Ma YK, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009;133:238-44
63. Dong X, Mattingly CA, Tseng M, et al. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 2009;72:9-17
64. Chattopadhyaya P, Shekunova BY, Yimb D, et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007;59:444-5
65. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002;82:105-14
66. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96
67. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77
68. Muller RH, Runge SA, Ravelli V, et al. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008;68:535-44
69. Florence AT, Gillan JMN. Biological implications of the use of surfactants in medicines: and the biphasic effects of surfactants in biological systems. Pest Sci 1975;6:429-39
70. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging Nanopharmaceuticals. Nanomedicine 2008;4:273-82
71. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995;9:87-93
72. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery for poorly water soluble drugs. Adv Drug Deliv Rev 1997;25:47-58
73. Pouton CW. Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. Int J Pharm 2000;17:335-48
74. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002;15:405-15
75. Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res 1992;9:87-93
76. Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15-23
77. Khoo SM, Humberstone AJ, Porter CJH, et al. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998;167:155-64
78. Newton M, Petersson J, Podczeck F, et al. The influence of formulation variables on the properties of pellets containing a self-emulsifying mixture. J Pharm Sci 2001;90:987-95
79. Chiellini EE, Bellich B, Macchiavelli S, et al. Solid double microemulsions for improved absorption of scarcely bioavailable drugs. Pharm J Slovenia 2003;54:469-70
80. Yi T, Wan J, Xu H, et al. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm 2008;70:439-44
81. Balakrishnan P, Lee BJ, Oh DH, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm 2009;72:539-45
82. Franceschinis E, Voinovich D, Grassi M, et al. Self-emulsifying pellets prepared by wet granulation in high-shear mixer: influence of formulation variables and preliminary study on the in vitro absorption. Int J Pharm 2005;291:87-97
83. Abdalla A, Mader K. Preparation and characterization of a self-emulsifying pellet formulation. Eur J Pharm Biopharm 2007;66:220-6
84. Iosio T, Voinovich D, Grassi M, et al. Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption. Eur J Pharm Biopharm 2008;69:686-97
85. Schaefer T, Holm P, Kristensen HG. Melt granulation in a laboratory scale high shear mixer. Drug Dev Ind Pharm 1990;16:1249-77
86. White JL, Szdlowski W, Min K, Kim MH. Twin screw extruders: development of technology analysis of flow. Adv Polym Technol 1987;7:295-332
87. Kim JW, Ulrich J. Prediction of degree of deformation and crystallization time of molten droplets in pastilation process. Int J Pharm 2003;257:205-15
88. Adeyeye CM, Price JC Development and evaluation of sustained release ibuprofen-wax microspheres. I. Effect of formulation variables on physical characteristics. Pharm Res 1991;8:1377-83
89. Paradkar AR, Maheshwari M, Ketkar AR, Chauhan B. Preparation and evaluation of ibuprofen beads by melt solidification technique. Int J Pharm 2003;255:33-42
90. Schaeffer T. Pelletisation with meltable binders in sustained release formulations with lipid based excipient. Bull Tech Gattefosse 2004;97:113-24
91. Voinovich D, Moneghini M, Perissutti B, Franceschinis E. Melt pelletization in high shear mixer using a hydrophobic melt binder: influence of some apparatus and process variables. Eur J Pharm BioPharm 2001;52:305-13
92. Schaefer T, Taagegaard B, Thomsen LJ, Kristensen HG. Melt pelletization in a high shear mixer. IV. Effects of process variables in a laboratory scale mixer. Eur J Pharm Sci 1993;1:125-31
93. McTaggart CM, Ganley JA, Sickmneller A, Walker SE. The evaluation of formulation and processing conditions of a melt granulation process. Int J Pharm 1984;19:139-48
94. Seo A, Holm P, Kristensen HG, Schaefer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int J Pharm 2003;259:161-71
95. Dordunoo SK, Ford JL, Rubinstein A. Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm 1991;17:1685-713
96. Damian F, Balton N, Naesens L, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci 2003;10:311-22
97. Jannin V. Thermoplastic pelletizing with a high-shear granulator. Glatt Int Times 2004;18:12-14
98. Maejima T, Osawa T, Nakajima K, Kobayashi M. Preparation ofspherical beads without any use of solvents by a novel tumbling melt granulation (TMG) method. Chem Pharm Bull 1997;45(3):518-24
99. Thies R, Kleinebudde P. Melt pelletisation of a hygroscopic drug in a high shear mixer. Part 1. Influence of process variables. Int J Pharm 1999;188:131-43
100. Voinovich D, Moneghini M, Perissutti B, et al. Preparation in high-shear mixer of sustained-release pellets by melt pelletization. Int J Pharm 2000;203:235-44
101. Schaefer T, Mathiesen C. Melt pelletization in a high shear mixer. VIII. Effects of binder viscosity. Int J Pharm 1996;139:125-38
102. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986;61:69-88
103. Ito Y, Kusawake T, Ishida M, et al. Oral olid gentamicin preparation using emulsifier and adsorbent. J Control Release 2005;105:23-31
104. Ito Y, Araik H, Uchino K, et al. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm 2005;289:69-77
105. Rodriguez L, Passerini N, Cavallari C, et al. Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing process. Int J Pharm 1999;183:133-43
106. Passerini N, Albertini B, Perissuti B, et al. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm 2006;318:92-102
107. Cavallari C, Rodriguez B, Albertini N, et al. Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained by ultrasound-assisted atomization. J Pharm Sci 2005;94:1124-34
108. Crowley MM, Zhang F, Repka MA, et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm 2007;33:909-26
109. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid solutions. Eur J Pharm Biopharm 2000;50:47-60
110. Nakamichi K, Nakano T, Yasuura H, et al. The role of kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int J Pharm 2002;241:203-11
111. Verreck G, Brewster ME. Melt extrusion-based dosage forms: excipients and processing conditions for pharmaceutical formulations. Bull Tech Gattefosse 2004;97:85-95
112. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 2002;54:107-17
113. Chopra R, Podczeck F, Newton JM, Alderborn G. The influence of pellet shape and film coating on the filling of pellets into hard shell capsules. Eur J Pharm Biopharm 2002;53:327-33
114. Montousse C, Pruvost M, Rodriguez F, Brossard C. Extrusion-spheronization manufacture of Gelucire (R) matrix beads. Drug Dev Ind Pharm 1999;25:75-80
115. Ghali ES, Klinger GH, Schwartz JB. Thermal-treatment of beads with wax for controlled release. Drug Dev Ind Pharm 1989;15:1311-28
116. Chatchawalsaisin J, Podczeck F, Newton JM, Boutel S. The preparation of spherical granules by extrusion/spheronization without microcrystalline cellulose. Pharm Technol 2004;16:21-7
117. Edimo A, Leterme P, Denis J, et al. Capacity of lipophilic auxiliary substances to give spheres by extrusion-spheronization. Drug Dev Ind Pharm 1993;19:827-42
118. Reitz C, Kleinebudde P. Spheronization of solid lipid extrudates. Powder Technol 2009;189:238-44
119. Hulsmann S, Backensfeld T, Keitel S, Bodmeier R. Melt extrusion-an alternative method for enhancing the dissolution rate of 17-bestradiol hemihydrate. Eur J Pharm Biopharm 2000;49:237-42
120. Serratoni M, Newton M, Booth S, Clarke A. Controlled drug release from pellets containing water-insoluble drugs dissolved in a selfemulsifying system. Eur J Pharm Biopharm 2007;65:94-8
121. Mehuys E, Vervaet C, Gielen I, et al. In vitro and in vivo evaluation of a matrix-in-cylinder system for sustained drug delivery. J Control Release 2004;96:261-71
122. Mehuys E, Vervaet C, Remon JP. Hot-melt extruded ethylcellulose cylinders containing a HPMC-Gelucire® core for sustained drug delivery. J Control Release 2004;94:273-80
123. Mehuys E, Remon JP, Korst A, et al. Human bioavailability of propranolol from a matrix-incylinder systemwith aHPMC-Gelucire® core. J Control Release 2005;107:523-36
124. Cheboyina S, O'Haver J, Wyandt CM. Mathematical model to predict the size of the pellets formed in freeze pelletization techniques: parameters affecting pellet size. J Pharm Sci 2006;95:167-80
125. Cheboyina S, Wyandt CM. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique I. Formulation and process variables affecting pellet characteristics. Int J Pharm 2008;359:158-66
126. Cheboyina S, Chambliss WG, Wyandt CM. A novel freeze pelletization technique for preparing matrix pellets. Pharm Tech 2004;28:98-110
127. Sandvik Materials Technology. Available from: http://www.processsystems. sandvik. com/[Last accessed on 10 September 2010]
128. Shukla D, Chakraborty S, Singh S, Mishra B. Pastillation-A novel technology for development of oral lipid based multiparticulate controlled release dosage form. Australasian Pharmaceutical Sciences Association Annual Conference, 9-11 December 2009; Program and Abstracts, Hobart; 2009. p. 106